Abstract
This study investigates the prevalence, incidence, and mortality of clinically diagnosed hypertrophic cardiomyopathy (HCM) in a Chinese population cohort of 21.9 million. Utilizing data from the Beijing Municipal Health Commission Information Center (2010–2019), we observed a significant rise in HCM prevalence (from 0.0069% to 0.076%) and incidence (from 6.85 to 11.76 per 100,000 person-years). While mortality remained relatively stable, the incidence of heart failure increased. Predictive modeling suggests that the population burden of HCM will double by 2029, emphasizing the need for enhanced clinical screening and management.
Introduction
Hypertrophic cardiomyopathy (HCM) is a primary genetic heart disease characterized by unexplained left ventricular hypertrophy. It is a major contributor to sudden cardiac death, heart failure, and stroke. Despite its clinical significance, large-scale epidemiological data for the Chinese population has been historically limited, often relying on small screening samples. This study aims to provide a comprehensive assessment of the HCM burden in Beijing, identifying demographic trends and forecasting future incidence to inform public health strategies.
Methods
The researchers utilized the Beijing Municipal Health Commission Information Center (BMHCIC) database, which aggregates clinical data from all 153 hospitals in the Beijing area. The study cohort grew from 19.62 million in 2010 to 21.90 million in 2019. HCM cases were identified via ICD-10 codes and validated by expert review. Trend analysis was conducted using Annual Percentage Change (APC), while future projections were generated using Poisson regression and the Gray Model 1,1 (GM [1,1]).
Results and Demographic Trends
The clinical detection of HCM in Beijing saw a dramatic increase over the decade. The prevalence rose more than tenfold, reaching 0.076% by 2019. Similarly, the annual incidence of new diagnoses increased significantly.
A notable "gender paradox" was observed: while males exhibited higher prevalence and incidence rates, females diagnosed with HCM faced a significantly higher mortality rate (4.20% vs. 2.70%, p < 0.001). Furthermore, while the individual risk of mortality remained stable during the study period, the incidence of HCM-related heart failure rose significantly (APPC: 8.4).
Future Projections
Based on the observed trends from the last decade, mathematical modeling predicts a continued surge in HCM cases. Both the Poisson regression and Gray models indicate that the number of incident HCM cases is expected to double by 2029, with projected increases ranging from 2.19-fold to 2.48-fold.
Discussion
The findings suggest that the current clinical prevalence (0.076%) is still below previous screening-based estimates (~0.16%), indicating a substantial "iceberg effect" where many asymptomatic individuals remain undiagnosed. The rising incidence likely reflects improved diagnostic capabilities and clinical awareness rather than a change in the underlying genetic frequency.
Limitations
The study is limited by its reliance on clinical records rather than universal genetic testing. Additionally, as a hospital-based registry, it may under-represent asymptomatic patients. Finally, while the Beijing cohort is massive, results may not fully generalize to rural regions with different healthcare access levels.
Conclusion
The burden of HCM in China is rising rapidly. With the projected doubling of cases over the next decade, there is an urgent need for proactive screening programs and improved management of HCM-related complications, particularly heart failure, to mitigate the long-term impact on public health.
Summary updated